Press Releases and Events
PRESS RELEASES
Press Release | May 22, 2026
Press Release | May 7, 2026
Crinetics Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update
READ MORE
Press Release | April 27, 2026
Crinetics Pharmaceuticals Announces the European Commission Approval of PALSONIFY® (Paltusotine) for the Treatment of Acromegaly in Adults
READ MORE
Press Release | April 8, 2026
Crinetics Pharmaceuticals to Report First Quarter 2026 Financial Results on May 7, 2026
READ MORE
Press Release | March 26, 2026
Crinetics Pharmaceuticals Announces Submission of Marketing Authorization Application in Brazil for Palsonify™ (Paltusotine) in Acromegaly
READ MORE
Press Release | February 26, 2026
Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
READ MORE
Press Release | February 5, 2026
Crinetics Pharmaceuticals to Participate in Two Upcoming Investor Conferences in March
READ MORE
Press Release | January 26, 2026
Crinetics Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026
READ MORE
Press Release | January 22, 2026
Crinetics Initiates Phase 2/3 Pediatric Trial Evaluating Atumelnant in Congenital Adrenal Hyperplasia (CAH)
READ MORE
Press Release | January 12, 2026
Crinetics Pharmaceuticals Announces January 2026 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
READ MORETransforming Endocrine Disease Treatment
Be the first to know about the advances we're making in endocrine-rooted care.
